FDA approves Keytruda for gastric cancer treatment
Merck, known as MSD outside of the US, has announced that the US Food and Drug Administration (FDA) has approved Keytruda in combination with fluoropyrimidine- and platinum-containing chemotherapy, for first-line treatment of adult patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma.
The approval follows data from the phase 3 KEYNOTE-859 trial, in which Keytruda in combination with chemotherapy reduced the risk of death by 22% compared to chemotherapy alone. Median overall survival (OS) was 12.9 months for Keytruda compared to 11.5 months with chemotherapy alone. […]
The post FDA approves Merck’s Keytruda for gastric cancer treatment appeared first on Pharmafile.
